Circulating miRNA-21-5p role in the development of orbitopathy in Graves disease

Non-coding RNA-mediated epigenetic alterations in Grave's ophthalmopathy: A scoping systematic review

“…The remaining 26 full texts were assessed, and six further articles were removed because three were not original studies [ [55] , [56] , [57] ], one lacked sufficient data [ 58 ], one was retracted [ 59 ], and another was in Chinese [ 58 ]. Finally, a total of 20 eligible articles remained [ [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] ].…”

“…3 a depicts the origin's comprehensive details. Case-control and cell culture design was utilized in nine studies [ [63] , [64] , [65] , [66] , 68 , 69 , 71 , 75 , 79 ], the case-control design was used in seven studies [ 60 , 61 , 72 , 74 , [76] , [77] , [78] ], cell culture design was used in three studies [ 62 , 67 , 73 ], and case-control, cell culture, and animal model design were utilized in one research [ 70 ] ( Fig. 3 b).…”

“…The present findings identify three serum miRNAs that may be associated with a poorer clinical outcome in GD patients. Furthermore, Al-Heety and Al-Hadithi [ 60 ] found that circulating miR-21–5p expression is significantly higher in individuals with orbitopathy than in patients without orbitopathy. According to the findings, the levels of TSH, Free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone receptor-antibodies (TSHR-Abs) are all positively linked with miR-21–5p.…”